1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market : Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market : Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies

  • November 2014
  • -
  • Frost & Sullivan
  • -
  • 68 pages

Summary

Table of Contents

Key Findings

• The number of MS prevalent cases globally (10 Million) is predicted to increase from in 2013 to by 2023.
• The United States MS market is entering a new phase of growth that is driven by the development of innovative therapeutic platforms.
• Recent therapeutics advances focus on a couple of factors:
o Improving tolerability of existing products specifically for interferon beta and glatiramer acetate
o Development of anti-inflammatory medications
o More clinical studies done investigating treatments in progressive MS
o Many clinical studies now include effects of Vitamin D in relapsing MS
• The existing interferon therapies—Avonex, Rebif, Betaseron/Extavia, and Plegridy, along with novel therapies such as Copaxone, Tysabri, Novantrone, Gilenya, and Tecfidera—have helped build a patient base in a market that has a very high degree of unmet medical needs.
• Oral therapies are revolutionizing the treatment paradigm of MS by improving dosing and patient compliance. Biogen’s Tecfidera, in particular, has been a game changer in the US MS market, stealing shares from older therapies.
• Newer treatments have the potential to treat refractory MS patients as well as patients suffering from primary progressive MS (PPMS).
• There is significant interest from big pharmaceutical, biotechnology, and specialty pharmaceutical companies to enter or expand their position within the market.

Methodology and Scope

• This research service focuses on prescription drugs used to treat MS.
• A product and pipeline assessment is provided for marketed and investigational drugs for the treatment of MS. Segmentation by drug class is provided, along with additional supporting information such as clinical trial timelines and results, projected launch timelines, and epidemiology.
• The information contained in this research service was derived from published sources, including disease organization Web sites; public health organization Web sites; company publications including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the Netherlands and Germany

  • April 2017
    10 pages
  • Anti-Infective  

  • Netherlands  

    Germany  

    Europe  

View report >

Global Therapy Market

  • April 2017
    10 pages
  • Therapy  

  • World  

View report >

Cardiovascular Disease Statistics in the US and the UK

  • April 2017
    8 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Cranberry Industry

16 days ago

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.